secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001104659-25-045310
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood Q1 net loss $37.4M; revenue down 45% YoY; raises adjusted EBITDA guidance to >$105M
--------------------------------------------------------------------------------

- Total revenue of $41.1M vs $74.9M in Q1 2024, down 45% YoY.
- GAAP net loss $37.4M ($0.23 loss per share) vs $4.2M loss a year ago.
- Adjusted EBITDA guidance raised to >$105M for FY 2025; on track to meet full-year guidance.
- LINZESS prescription demand grew 8% YoY in Q1 2025, in line with expectations.
- Company is exploring strategic alternatives to maximize stockholder value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465925045310/0001104659-25-045310-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465925045310/tm2514185d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-045310

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer